Catalyst
Slingshot members are tracking this event:
Data from Novartis' (NVS) RTH258 (brolucizumab) Phase 3 study in nAMD patients released
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 20, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Neovascular Amd, Rth258, Brolucizumab
